Publication | Open Access

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCisplatin Versus GemcitabineCancer TreatmentOncologyRadiation OncologyLung CancerPhase 3